<DOC>
	<DOC>NCT01001468</DOC>
	<brief_summary>The purpose of this study is to examine the efficacy, safety and tolerability of VB-201 as compared with placebo on measures of disease activity in patients with psoriasis.</brief_summary>
	<brief_title>Study to Assess VB-201 in Patients With Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male or female Patients, ≥18 to ≤75 years of age, who have a diagnosis of chronic plaque psoriasis for at least 6 months Nonanorexic subjects with a BMI ≥20 Psoriasis Area and Severity Index (PASI) score of ≥12 Plaque psoriasis covering ≥10% of body surface area (BSA) Psoriasis severity at least moderate, scoring at least 3 on the 0 to 5 point Physician Global Assessment (PGA) scale The subject presents with the predominant type of psoriasis as guttate, erythrodermic, inverse, pustular or palmoplantar or an unstable form of psoriasis The subject has not undergone washout periods of sufficient duration for the following treatments at Baseline: Topical psoriasis treatments; Systemic, oral or injected, psoriasis treatments; Phototherapy The subject anticipates getting enough ultraviolet light during the study to cause psoriasis to improve The subject has a known allergy or sensitivity to the study treatment(s) or to any of the excipients contained in the study drug formulation History of cancer, the exception is skin cancer Has a clinically significant systemic infection within 30 days of Day 0, or a history or presence of recurrent or chronic infection Evidence of tuberculosis as indicated by a positive tuberculin skin test or a quantiferon test in subjects known to have a + PPD and a negative chest xray at screening History of clinically significant hypoglycemia Subjects with currently active peptic ulcer / gastroesophageal reflux disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>